Latest available resultsQuarter ended June 30, 202610-Q · August 3, 2026
Filed with the SECAbbVie Inc.
ABBVPharma & biotech
Next reportOctober 29, 2026Analyst forecast 3.918 $/share
Revenue
$16.99B
▲ +10.2% vs prior year% YoY
Net income
$3.61B
▲ +285.2% vs prior year% YoY
EPS
2.03$
▲ +290.4% vs prior year% YoY
Net margin
21.3%
▲ +15.2 percentage points vs prior year pp YoY
Revenue▲ +10.2 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +285.2 %
EPS▲ +290.4 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $16.99B | |
| Gross profit | $12.70B | 74.7 % |
| Operating income | $6.43B | 37.9 % |
| Net income | $3.61B | 21.3 % |
| R&D | — | never filed |
| EPS (diluted) | 2.03 $ | |
| Balance sheet | ||
| Assets | $135.12B | |
| Liabilities | $141.00B | |
| Equity | −$5.89B | |
| Cash | $6.57B | |
| Capital | ||
| Shares outstanding | 1.77B | as of 2026-07-27 |
| Public float | — | |